Our R&D strategy focuses on diseases where our science and technology support the promise for major advancements in available treatments. We aim to fully exploit these opportunities through astute investments in our programmes, and a sharp focus on execution.
Our pipeline comprises two therapeutic franchises: Oncology, and Immunotherapy. The oncology programmes use each of our three core technologies. Our immune-oncology programmes use our gold nanoparticle technology.